OA11952A - Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists. - Google Patents

Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists. Download PDF

Info

Publication number
OA11952A
OA11952A OA1200100314A OA1200100314A OA11952A OA 11952 A OA11952 A OA 11952A OA 1200100314 A OA1200100314 A OA 1200100314A OA 1200100314 A OA1200100314 A OA 1200100314A OA 11952 A OA11952 A OA 11952A
Authority
OA
OAPI
Prior art keywords
dihydrochloride
crystalline
anhydrous
dihydrate
water
Prior art date
Application number
OA1200100314A
Other languages
English (en)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Michael Jon Gumkowski
David Joseph Muehlbauer
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11952A publication Critical patent/OA11952A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA1200100314A 1999-06-22 2000-06-06 Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists. OA11952A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14023399P 1999-06-22 1999-06-22

Publications (1)

Publication Number Publication Date
OA11952A true OA11952A (en) 2006-04-13

Family

ID=22490317

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100314A OA11952A (en) 1999-06-22 2000-06-06 Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists.

Country Status (35)

Country Link
US (1) US6262067B1 (hr)
EP (1) EP1187834A1 (hr)
JP (1) JP2003502425A (hr)
KR (1) KR20020030280A (hr)
CN (1) CN1390216A (hr)
AP (1) AP2001002367A0 (hr)
AR (1) AR024411A1 (hr)
AU (1) AU767336B2 (hr)
BG (1) BG106205A (hr)
BR (1) BR0011835A (hr)
CA (1) CA2375265A1 (hr)
CO (1) CO5190663A1 (hr)
CZ (1) CZ20014458A3 (hr)
DZ (1) DZ3055A1 (hr)
EA (1) EA004264B1 (hr)
EC (1) ECSP003538A (hr)
EE (1) EE200100698A (hr)
HR (1) HRP20010920A2 (hr)
HU (1) HUP0201694A3 (hr)
IL (1) IL146410A0 (hr)
IS (1) IS6161A (hr)
MA (1) MA26744A1 (hr)
MX (1) MXPA02000033A (hr)
NO (1) NO20016187D0 (hr)
NZ (1) NZ515348A (hr)
OA (1) OA11952A (hr)
PA (1) PA8496701A1 (hr)
PE (1) PE20010322A1 (hr)
PL (1) PL352899A1 (hr)
SK (1) SK18672001A3 (hr)
TN (1) TNSN00137A1 (hr)
TR (1) TR200103688T2 (hr)
UY (1) UY26211A1 (hr)
WO (1) WO2000078759A1 (hr)
ZA (1) ZA200110387B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
EP1551846A1 (en) * 2002-10-04 2005-07-13 Merck Sharp & Dohme Ltd. Azabicyclic spiroether derivatives as receptor antagonists
PT1569627E (pt) 2002-12-11 2009-01-20 Taro Pharma Ind Método de tratamento de doenças do movimento utilizando derivados do ácido barbitúrico
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
SK390692A3 (en) * 1991-05-31 1998-02-04 Pfizer Quinuclidine derivatives, preparation method thereof and use
ATE147385T1 (de) * 1992-11-12 1997-01-15 Pfizer Chinuclidin derivat als substanz p antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
SK18672001A3 (sk) 2002-08-06
AR024411A1 (es) 2002-10-02
CZ20014458A3 (cs) 2002-03-13
DZ3055A1 (fr) 2004-03-27
US6262067B1 (en) 2001-07-17
TR200103688T2 (tr) 2002-12-23
BR0011835A (pt) 2002-03-05
AU4774500A (en) 2001-01-09
HRP20010920A2 (en) 2003-02-28
PA8496701A1 (es) 2002-07-30
ECSP003538A (es) 2002-01-25
WO2000078759A1 (en) 2000-12-28
CN1390216A (zh) 2003-01-08
EA200101179A1 (ru) 2002-06-27
MXPA02000033A (es) 2002-07-02
IS6161A (is) 2001-11-13
CA2375265A1 (en) 2000-12-28
AU767336B2 (en) 2003-11-06
NZ515348A (en) 2003-07-25
EA004264B1 (ru) 2004-02-26
NO20016187L (no) 2001-12-18
PE20010322A1 (es) 2001-03-14
HUP0201694A2 (en) 2002-09-28
PL352899A1 (en) 2003-09-22
AP2001002367A0 (en) 2001-12-31
KR20020030280A (ko) 2002-04-24
HUP0201694A3 (en) 2002-10-28
JP2003502425A (ja) 2003-01-21
CO5190663A1 (es) 2002-08-29
TNSN00137A1 (fr) 2002-05-30
MA26744A1 (fr) 2004-12-20
EE200100698A (et) 2003-02-17
NO20016187D0 (no) 2001-12-18
IL146410A0 (en) 2002-07-25
ZA200110387B (en) 2002-12-19
EP1187834A1 (en) 2002-03-20
UY26211A1 (es) 2001-01-31
BG106205A (bg) 2002-07-31

Similar Documents

Publication Publication Date Title
CA1180696A (en) Method for producing chemical compounds
MX2007001854A (es) Hidratos de polimorfos de 4-[[(7 -r)-8- ciclopentil-7 -etil-5, 6, 7, 8-tetrahidro-5 -metil-4-6 -oxo-2-piperidinil] amino]-3 -metoxi-n- (1-metil-4 -piperidinil)-benzamida, metodos para la produccion de los mismos, y uso de los mismos como medicamentos
OA11952A (en) Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists.
US5143935A (en) Benzamide derivatives
SK9398A3 (en) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2- -methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
WO1994022843A1 (en) 2-substituted morpholine and thiomorpholine derivatives as gaba-b antagonists
AU767334B2 (en) Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
IE55232B1 (en) "n-(2-methoxyethyl)-noroxymorphone"
EP0240986B1 (en) D-nor-7-ergoline derivatives, process for preparing them, pharmaceutical composition and use
GB2065113A (en) Ergoline derivatives, their production and pharmaceutical compositions containing them